GP2d

Cat.No.: CSC-C9456J

Species: Homo sapiens (Human)

Source: Intestine; Colon

  • Specification
  • Background
  • Scientific Data
  • Q & A
  • Customer Review
Cat.No.
CSC-C9456J
Description
GP2d has been established from the same adenocarcinoma as GP5d. This has been confirmed by STR profiling at. The cells were derived from a local recurrence of Duke's grade B, poorly differentiated carcinoma of the colon from a 71 year old female at surgical resection. The patient received no preoperative chemo- or radiotherapy and had a strong family history of colon cancer with two first degree relatives dying of the disease below the age of 55 years. Both clones possess genetic changes consistent with the pattern of tumour progression in colon cancer but are morphologically distinct. An interstitial deletion on chromosome 5 (region 14q to 22q) and an inverted duplication of bands 10q11 and 10q21 has been reported. Both cell lines contain a normal copy of the ki-ras gene and a copy with a transition in codon 12. GP2d cells show growth response to EGF, TGF alpha or insulin with an increase in cell numbers. Amphiregulin mRNA is abundant in GP2d but almost undetectable in GP5d.
Species
Homo sapiens (Human)
Source
Intestine; Colon
Recommended Medium
DMEM + 2mM Glutamine + 10% Fetal Bovine Serum (FBS)
Disease
Colon Adenocarcinoma
Storage
Liquid Nitrogen (-180 °C).
Storage and Shipping
Creative Bioarray ships frozen cells on dry ice. On receipt, immediately transfer frozen cells to liquid nitrogen (-180 °C) until ready for experimental use. Never can cryopreserved cells be kept at -20 °C.
Synonyms
Gp2d; Gp2D; GP2D
Citation Guidance
If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the PubMed ID of your paper to get a coupon.

The GP2D cell line was established from an adenocarcinoma identified as a local recurrence of Duke's grade B colon cancer. This classification indicates that the tumor was originally diagnosed at a stage where there was significant local invasion but no distant metastasis. The background of GP2D is particularly noteworthy as it originated from a 71-year-old female, reflecting a demographic commonly affected by colorectal cancer, where age and sex can play crucial roles in tumor characteristics and patient outcomes.

The GP2D cell line is categorized as a poorly differentiated carcinoma, which suggests that the malignant cells exhibit a high degree of abnormality compared to normal colon tissue. Poorly differentiated tumors often demonstrate aggressive behavior, increased propensity for metastasis, and poorer prognosis when compared to well-differentiated tumors. This makes GP2D a valuable model for studying aggressive colorectal cancers, as it can help researchers explore the underlying mechanisms driving tumor progression and resistance to treatment.

Furthermore, the establishment of GP2D has been validated through short tandem repeat (STR) profiling, which confirms its genetic identity and origin from the same adenocarcinoma as the related GP5D cell line. This genetic verification ensures that studies conducted with GP2D can yield reliable and reproducible results when investigating drug responses or molecular pathways associated with poorly differentiated CRC. The insights obtained from GP2D are crucial for the development of therapeutic strategies aimed at treating patients with similar aggressive tumor profiles.

The farnesyl transferase inhibitor KO-2806 re-sensitizes relapsing tumors to RAS inhibition

bioRxiv | DOI | Paper |

Background

The preprint investigates resistance to RAS-targeted therapies in KRAS-mutant NSCLC and CRC. Persistent mTORC1 activity is identified as a nongenetic driver of inherent and adaptive resistance. The farnesyl transferase inhibitor KO-2806 blocks RHEB-mediated mTORC1 activation while sparing mTORC2. Adding KO-2806 to mutant-selective or pan-RAS inhibitors caused rapid, durable regression in relapsing tumors, including models progressing on adagrasib, sotorasib, MRTX1133, or RMC-6236. The findings support KO-2806 as a companion inhibitor to re-sensitize tumors to RAS inhibition after prior RAS inhibitor exposure.

Key Findings

Persistent mTORC1 signaling was a frequent nongenetic mechanism of inherent and adaptive resistance to RAS inhibition in KRAS-mutant NSCLC and CRC. KO-2806, a potent and selective farnesyl transferase inhibitor, blocked RHEB farnesylation and mTORC1 activation while sparing mTORC2. In NSCLC models, combining KO-2806 with adagrasib deepened and prolonged tumor regressions, prevented regrowth after treatment cessation, and inhibited mTOR substrates. In CRC models, KO-2806 blocked mTOR rebound after MRTX1133 or RMC-6236 and enhanced tumor growth inhibition. Importantly, adding KO-2806 to tumors progressing on mutant-selective RAS inhibitors or the pan-RAS inhibitor RMC-6236 induced rapid and durable regressions, whereas switching inhibitor class alone was insufficient. The results establish mTORC1 as a key escape pathway and support KO-2806 as a RAS companion inhibitor.

Contribution

Creative Bioarray provided the GP2D colorectal cancer cell line used in this study. This cell line was central to establishing in vitro spheroid and in vivo xenograft models for evaluating KO-2806 plus RAS inhibitors, helping demonstrate mTORC1 rebound blockade and tumor regressions.

KO-2806 re-sensitizes relapsing tumors to mutant-selective or pan-RAS inhibition.
Fig. 1. KO-2806 re-sensitizes relapsing tumors to mutant-selective or pan-RAS inhibition.

Distinct ERK and PI3K dependencies mediate a heterogeneous response to RAS(ON) inhibition in KRAS-mutant colorectal cancer

Cell Reports | DOI | Paper |

Background

This study evaluates RMC-7977, a RAS(ON) multi-selective inhibitor, in KRAS-mutant colorectal cancer models, revealing heterogeneous responses. PI3K signaling and cyclin D1 expression correlate with resistance. Stratifying tumors by ERK dependence of cyclin D1 identifies two groups: ERK-dependent tumors respond to vertical RAS/MEK inhibition, whereas PI3K-dependent tumors benefit from parallel RAS/PI3K inhibition. These combinations suppress CCND1 mRNA, induce cell cycle arrest, and promote apoptosis. Cyclin D1 is proposed as a key integrator and functional readout of upstream signaling, informing precision combination strategies.

Key Findings

RMC-7977 produced heterogeneous growth inhibition across 14 KRAS-mutant CRC cell lines. While pERK was uniformly inhibited early, p4E-BP1 S65, pAKT S473, c-Myc, β-catenin, and especially cyclin D1 correlated with resistance. The ERK dependence of cyclin D1, determined by differential CCND1 mRNA regulation, separated tumors into group 1 (fully ERK-dependent) and group 2 (partially ERK-dependent/PI3K-maintained). In group 1, RAS plus MEK inhibition prevented ERK rebound, suppressed cyclin D1, caused cell cycle arrest and apoptosis, and was superior in SW837 xenografts. In group 2, PI3K signaling sustained CCND1 mRNA; RAS plus PI3K inhibition synergistically reduced cyclin D1, induced G1 arrest/apoptosis, and was more effective in GP2D CDX and HER2-amplified PDX models. CDK4/6 inhibition or CCND1 knockdown was limited by adaptive cyclin D2/E1 upregulation, often RAS-dependent. Thus, cyclin D1 integrates ERK/PI3K inputs and guides vertical versus parallel combination therapy.

Contribution

Creative Bioarray provided the COLO678 and GP2D colorectal cancer cell lines used in this study (Key Resources Table). These models supported the in vitro RAS(ON) inhibitor response panel, ERK/PI3K/cyclin D1 signaling analyses, and the GP2D CDX in vivo validation of combination strategies.

Grouping of KRAS-mutant CRC tumors based on the ERK dependence of cyclin D1 expression
Fig. 2. Grouping of KRAS-mutant CRC tumors based on the ERK dependence of cyclin D1 expression

The Farnesyl Transferase Inhibitor Darlifarnib (KO-2806) Resensitizes Relapsing Tumors to RAS Inhibition

Cancer Research | DOI | Paper |

Background

Resistance limits RAS-targeted therapies. This study identifies persistent mTORC1 signaling as a nongenetic driver of intrinsic and adaptive resistance in KRAS-mutant NSCLC and colorectal cancer. The farnesyl transferase inhibitor darlifarnib (KO-2806) blocks RHEB-dependent mTORC1 activation while sparing mTORC2. Combining KO-2806 with mutant-selective or pan-RAS inhibitors caused rapid and durable regression of tumors progressing on prior RAS inhibitor treatment, whereas switching RAS inhibitor classes alone was insufficient. KO-2806 represents a promising companion agent to resensitize relapsing tumors to RAS inhibition.

Key Findings

Persistent mTORC1 activity was identified as a frequent, nongenetic mediator of intrinsic and adaptive resistance to RAS inhibition in KRAS-mutant NSCLC and colorectal cancer. KO-2806 is a potent, selective farnesyl transferase inhibitor that blocks RHEB farnesylation and RHEB-dependent mTORC1 activation while sparing mTORC2, with improved pharmacokinetics over tipifarnib. In NSCLC models, adding KO-2806 to the KRASG12C inhibitors adagrasib or sotorasib, or to the pan-RAS inhibitor RMC-6236, deepened and prolonged tumor regressions. Importantly, KO-2806 resensitized tumors that had progressed on RAS inhibitor monotherapy, producing rapid and durable regressions, whereas switching to another RAS inhibitor class alone only slowed or failed to control growth. In colorectal cancer models, KO-2806 plus MRTX1133 or RMC-6236 blocked mTORC1 rebound, enhanced signaling inhibition, and reversed relapse. These findings establish mTORC1 as a key escape pathway and support combining KO-2806 with RAS inhibitors to overcome resistance.

Contribution

Creative Bioarray provided the GP2D colorectal cancer cell line used in key in vitro and in vivo experiments. This line enabled evaluation of KO-2806 with MRTX1133/RMC-6236 in KRASG12D-mutant colorectal cancer models, supporting the central finding that FTase inhibition resensitizes relapsing tumors to RAS inhibition.

KO-2806 is a next-generation FTI with increased potency and improved PK properties compared with tipifarnib.
Fig. 3. KO-2806 is a next-generation FTI with increased potency and improved PK properties compared with tipifarnib.

Genetic Analyses of GP2d and GP5d Cell Lines

Two morphologically distinct cell lines, GP2d and GP5d, derived from the same adenocarcinoma of the colon, have been established and characterized. Genetic analyses were performed to determine whether the differing morphologies of the 2 clones arose as a consequence of a detectable genetic difference between the cells. Confirmation of the genetic identity of the cells was obtained by DNA fingerprinting. DNA profiles of GP2d and GP5d were shown to match for each of the 4 single locus probes used; profiles of control DNA obtained from HT29 cells showed no match with either GP2d or GP5d.

Metaphase spreads examined from both cell lines showed identical female karyotypes (Fig. 1). Each possessed 46 chromosomes and both had an interstitial deletion from the long arm of chromosome 5 in the region 14q to 22q. This deletion is typical of colonic adenocarcinomas. Both clones also possessed additional material on the long arm of chromosome 10; this appeared to be an inverted duplication of bands 1Oq11 and 10q21. This region of chromosome 10 is known to contain the ret proto-oncogene.

Direct sequencing of the Ki-ras gene detected a G to A transition in codon 12 in both cell lines, resulting in a Gly to Asp substitution (Fig. 2). Both cell lines contained a normal copy of the Ki-ras gene, as indicated by the equal intensity of the bands derived from the normal and mutant genes. p53 mutations were examined by SSCP analysis; no band shifts were evident in either cell line compared with normal DNA amplification products for exons 5-8 of the p53 gene.

Since karyotype analysis indicated an abnormality on chromosome 10 in the region of the ret proto-oncogene, the 2 colon carcinoma cell lines were analyzed for rearrangement of this gene by Southern hybridization with a ret cDNA probe which detects fragments of 6.3 kb and 6.6 kb after EcoRI digestion (Fig. 3). Rearrangement of the ret gene results in the juxtaposition of the ret transmembrane and tyrosine kinase domains with other 5' expressed sequences. This rearrangement occurs within an intronic sequence contained in the 6.3-kb EcoRI fragment and can be detected by an alteration in the size of this fragment. Neither of the carcinoma cell lines showed any evidence of alteration in this fragment (Fig. 3), and no additional bands were observed even after prolonged exposure to the autoradiogram. Hybridization was also performed on BamHI-digested DNA, but again no rearrangements were detected.

The figure shows a typical chromosome spread obtained for GP2d which possesses a female kat-yotype of 46 chromosomes (a). The abnormalities are represented diagrammatically in (b).Fig. 4. Karyotypic analysis of GP2d. The figure shows a typical chromosome spread obtained for GP2d which possesses a female kat-yotype of 46 chromosomes (a). The abnormalities are represented diagrammatically in (b). (Solic N, et al., 1995)

The figure shows the autoradiograph of the sequencing gels obtained for GP2d (a) and GP5d (b).Fig. 5. Analysis of the Ki-ras gene in GP2d and GP5d. The figure shows the autoradiograph of the sequencing gels obtained for GP2d (a) and GP5d (b). (Solic N, et al., 1995)

Southern blot analysis of EcoRI-digested DNA extracted from normal human lymphocytes (lanes 1) and GP2d and GP5d (lanes 2 and 3) and hybridized with a ret cDNA probe.Fig. 6. Analysis of the ret gene in GP2d and GP5d. Southern blot analysis of EcoRI-digested DNA extracted from normal human lymphocytes (lanes 1) and GP2d and GP5d (lanes 2 and 3) and hybridized with a ret cDNA probe. (Solic N, et al., 1995)

E-Cadherin in Human Colorectal Carcinoma Cells

Human colorectal cancer cell lines derived from patients were screened for E-cadherin mutations. Single-base deletion mutations were found in nucleotide repeat regions at codons 120 and 126, resulting in frameshifts and premature stops in four RER+ colorectal cancer cell lines (LS174T, HCT116, GP2d, and GP5d) derived from three patients (Fig. 4). These truncations lie in the N-terminal, extracellular domain of the protein and are predicted to generate small, secreted E-cadherin fragments with loss of surface expression and no cellular adhesive capacity. Such small products may even interfere with the normal function of full-length E-cadherin molecules. These frameshift mutations were present as heterozygotes, although an additional single-base substitution was detected at the exon 8 splice donor site in LS174T, with apparent retention of a wild-type allele in HCT116, GP2d, and GP5d.

Single-strand conformational polymorphism (SSCP) analysis of exon 3 of E-cadherin, showing the heterozygous band mobility of LS174T (arrow). Sequencing showed this to be a single base pair deletion causing a premature stop at codon 216.Fig. 7. Single-strand conformational polymorphism (SSCP) analysis of exon 3 of E-cadherin, showing the heterozygous band mobility of LS174T (arrow). (Efstathiou JA, et al., 1999)

Ask a Question

Write your own review

For research use only. Not for any other purpose.

Hot Products